Author

V. Makarov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:cryo-EM· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

O. Riabova· 4 shared N. Monakhova· 2 shared S. Ekins· 2 shared T. R. Lane· 2 shared A. C. Puhl· 1 shared A. Desrichard· 1 shared A. Egorova· 1 shared A. Ho· 1 shared

Activity by Year

2017-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

O. Riabova

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Strain dependent structural effects and in vivo efficacy of enterovirus-D68 inhibitors

T. R. Lane, J. Fu, B. Sherry, B. Tarbet, B. Hurst, O. Riabova, E. Kazakova, A. Egorova, P. Clarke, J. S. Leser, J. Frost, M. Rudy, K. Tyler, T. Klose, R. J. Kuhn, , S. Ekins

This study develops a potent EV-D68 inhibitor, 11526092, showing improved in vitro potency and in vivo efficacy compared to pleconaril, with strain-dependent structural effects observed via cryo-EM.

bioRxiv · Dec 24, 2021 · PreprintPharmacology & Toxicology

Pyronaridine Protects Against SARS-CoV-2 in Mouse

A. C. Puhl, G. F. Gomes, S. Damasceno, A. S. de Godoy, G. D. Noske, A. M. Nakamura, V. O. Gawrijuk, R. S. Fernandes, N. Monakhova, O. Riabova, T. R. Lane, V. Makarov, F. P. Veras, S. S. Batah, A. T. Fabro, , S. Ekins

Pyronaridine reduces SARS-CoV-2 viral load and lung pathology in mice, with in vitro inhibition of viral PLpro and host kinase CAMK1.

bioRxiv · Sep 30, 2021 · PreprintPharmacology & Toxicology

Exposure to nitric oxide drives transition to differential culturability in Mycobacterium tuberculosis

S. M. Glenn, B. Gap-Gaupool, E. Milburn, O. Turapov, M. Crosatti, J. Hincks, B. Stewart, J. Bacon, S. L. Kendall, M. I. Voskuil, O. Riabova, N. Monakhova, J. Green, S. J. Waddell, V. Makarov, G. V. Mukamolova

This study shows that nitric oxide exposure leads to the formation of Rpf-dependent differentially culturable Mycobacterium tuberculosis subpopulations, which are resistant to standard diagnostics and treatments.

bioRxiv · Sep 28, 2021 · PreprintMicrobiology

Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis

J. Piton, A. Vocat, A. Lupien, C. S.-Y. Foo, O. Riabova, V. Makarov, S. T. Cole

The paper designs and characterizes sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from M. tuberculosis, finding they have improved solubility but lower activity than MCZ.

bioRxiv · Apr 10, 2018Pharmacology & Toxicology

Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions

M. Dalin, N. Katabi, M. Persson, K.-W. Lee, V. Makarov, A. Desrichard, L. Walsh, L. West, Z. Nadeem, D. Ramaswami, J. Havel, F. Kuo, K. Chadalavada, G. Nanjangud, N. Riaz, , L. G. T. Morris

This study identifies prevalent oncogenic gene fusions in myoepithelial carcinoma through genomic analysis, highlighting TGFBR3-PLAG1 as a key fusion and potential therapeutic target.

bioRxiv · Jun 9, 2017Cancer Biology